Ascentage Pharma Group International
AAPG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023311
No open-market purchases or sales by Ascentage Pharma Group International insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $263.5K in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Ascentage Pharma Group International as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +2 vs. Q2 2025
- Shares held
- 94.1K
- +12.3K (+15.0%) vs. Q2 2025
- Total value
- $3.69M
- +$465.8K (+14.5%) vs. Q2 2025
- New holders
- 6
- 3 more added
- Sold out
- 4
- 4 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AAPG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $263.5K |
| Q1 2026 | 7 | $721.7K |
| Q4 2025 | 12 | $1.25M |
| Q3 2025 | 14 | $3.69M |
| Q2 2025 | 12 | $3.22M |
| Q1 2025 | 6 | $5.21M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Ascentage Pharma Group International; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 18,345 | $716.2K | 0.00% | +10,988+149.4% | Added |
| XY Capital Ltd | 18,120 | $707.4K | 0.59% | +12,530+224.2% | Added |
| Point72 (DIFC) Ltd | 17,930 | $700.0K | 0.05% | −2,960−14.2% | Reduced |
| NEOS Investment Management LLC | 10,385 | $412.2K | 0.00% | −5,110−33.0% | Reduced |
| Tema ETFs LLC | 10,385 | $405.4K | 0.03% | −5,110−33.0% | Reduced |
| Citadel Advisors LLC | 9,652 | $383.1K | 0.00% | +9,652 | New |
| Abc Arbitrage SA | 5,230 | $204.2K | 0.02% | +5,230 | New |
| Mirae Asset Global Investments Co., Ltd. | 2,463 | $96.2K | 0.00% | +2,463 | New |
| Tower Research Capital LLC (TRC) | 829 | $32.4K | 0.00% | +829 | New |
| Advisor Group Holdings, Inc. | 220 | $8.48K | 0.00% | +220 | New |
| Morgan Stanley | 203 | $7.92K | 0.00% | −753−78.8% | Reduced |
| Bank of America Corp | 180 | $7.03K | 0.00% | +180 | New |
| Bell Investment Advisors, Inc | 67 | $2.62K | 0.00% | 00.0% | Unchanged |
| EverSource Wealth Advisors, LLC | 67 | $2.62K | 0.00% | +43+179.2% | Added |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −9,933−100.0% | Sold out |
| Chevy Chase Trust Holdings, Inc. | 0 | $0 | 0.00% | −5,753−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −211−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −6−100.0% | Sold out |